Cooper Companies Inc
LSE:0I3I
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its 3-Year Average (5), the stock would be worth $91.31 (41% upside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 3.6 | $64.75 |
0%
|
| 3-Year Average | 5 | $91.31 |
+41%
|
| 5-Year Average | 5 | $90.09 |
+39%
|
| Industry Average | 18.7 | $338.7 |
+423%
|
| Country Average | 16.7 | $302.51 |
+367%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
C
|
Cooper Companies Inc
LSE:0I3I
|
12.8B USD | 3.6 | 1.8 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
58.8B USD | 0 | 0 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.7T JPY | 36.2 | 38.6 | |
| CH |
|
Alcon AG
SIX:ALC
|
29.2B CHF | 17.4 | 37.3 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
94.7B DKK | 16.5 | 23.5 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
13.5B USD | 20.9 | 33 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.3B GBP | 15.2 | 32.7 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.6B USD | 36.2 | -15.5 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
890.2B JPY | 20.8 | 50.3 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
36.7B CNY | 24.7 | 23.3 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8T KRW | -86.3 | -36.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 11.7 |
| Median | 16.7 |
| 70th Percentile | 23.6 |
| Max | 3 178 983.5 |
Other Multiples
Cooper Companies Inc
Glance View
In the world of healthcare innovation, Cooper Companies Inc. etched its name as a significant player, specializing in creating products that enhance lives, particularly in the fields of vision care and women’s health. Established in 1958, Cooper Companies evolved to become a holding company operating through its two primary business units: CooperVision and CooperSurgical. CooperVision is renowned globally for its expertise in contact lenses, providing a diversified range of lenses to correct myopia, hyperopia, astigmatism, and presbyopia. By leveraging cutting-edge technology and a deep understanding of wearer needs, CooperVision caters to a wide spectrum of users, from daily disposables to specialty lenses, thus driving consistent revenue through the consumable nature of its products. CooperSurgical, on the other hand, focuses on solutions for women’s health, offering a gamut of medical instruments, devices, and diagnostics. This unit extends Cooper Companies' footprint into the realms of fertility products, contraception, and obstetrics. By addressing key segments of the women’s health market, CooperSurgical supports clinical needs across a woman’s lifespan. Revenue opportunities here arise from both its durable medical equipment and consumable products, which ensure a stream of repeat business as healthcare providers replenish their supplies. Together, these divisions enable Cooper Companies to not only secure a robust market position but also continuously explore new areas for growth and expansion within the broader healthcare industry.